Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
about
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesResponse to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancerHighly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP methodSpatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option.Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis.Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.Combination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis.Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysisAnti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis.Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis.A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test.The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement.Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).Immunotherapy as an Option for Cancer Treatment.Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab.
P2860
Q26738801-68689374-D1C4-43AA-8ADC-9992E8A9FFCAQ33441453-69997175-3C18-45CE-9F5D-C28BB805E144Q36074183-E4460E87-66FF-44CA-B3DD-0BEC8769DD44Q36167042-54829289-79B6-4780-A04F-20B9F370F45BQ37124712-1E4DF538-6319-42C8-934B-9E90D78C24E5Q37235153-D19C7421-BCD9-479C-A36E-2CEFA8C09F44Q37327850-9790D515-6BEB-4619-A53C-99EF6EC58919Q37429996-26A375C4-D3B2-408A-A8C9-14B6BD07210EQ37530472-1C7D50BB-E29C-477C-AE45-F79312CEED54Q38375269-31DC7BA8-BEDC-43F6-AE90-6F7A630207D3Q38644154-2F53281E-3A1F-4A3F-BAAA-43746FC0D18CQ38684918-141F94AD-BA89-4277-9AC7-63E3B3E226C2Q38755440-A539CFD1-4BDC-45F3-AE1C-3198325A9280Q38787278-1890D1E7-68F3-4082-AFA2-325C69A39D32Q38811461-4B80B2C2-E10B-455D-9CE7-6E56FA5DB165Q41095121-0D97F2F8-3EA4-4E23-9AA6-3BE822965150Q41593315-B227A080-540D-469D-9F3E-F48770A5A420Q41918758-E86EE4E4-DA2C-44A9-9490-C8BA9D144A7AQ47132740-F5736682-AF58-4D64-B921-EA446B2FF246Q47142532-FD3CE06A-F7F2-4003-9C6C-C972235A511EQ47675408-8B45F3C8-2E3E-4CDE-B850-5B110DEF63FAQ47679286-5C314992-8E28-4631-BB92-A90BCF015AE8Q47695912-A6ADA0C8-8B33-4D40-B07D-F140C2C83513Q48194503-4697B2C5-367F-4D4A-99AC-262A9B88BE32Q55286218-FD626204-B3AB-475A-8F0C-14B57DE842C1Q55518414-98EA49EC-5F65-4E97-A573-D1711A82C90B
P2860
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@en
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@nl
type
label
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@en
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@nl
prefLabel
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@en
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@nl
P2093
P921
P356
P1476
Impact of Subsequent Therapies ...... Metastatic Colorectal Cancer.
@en
P2093
Alexander Kiani
Andreas Jung
Christian Lerchenmüller
Christoph Kahl
Dominik P Modest
Frank Kullmann
Gernot Seipelt
Ludwig Fischer von Weikersthal
Markus Möhler
Martina Stauch
P304
P356
10.1200/JCO.2015.61.2887
P407
P577
2015-08-10T00:00:00Z